Title:
CANCER TREATMENT AGENT INCLUDING MALT1 INHIBITING DRUG AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2023/149450
Kind Code:
A1
Abstract:
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate, or a solvate thereof, demonstrates a strong antitumor effect, and thus is useful in treating blood cancer.
More Like This:
Inventors:
KOZAKI RYOHEI (JP)
FUJIKAWA RYU (JP)
ONO KAZUYA (JP)
MORISHITA DAISUKE (JP)
SATOH YOSHIHIKO (JP)
MIZUTANI AKIO (JP)
FUJIKAWA RYU (JP)
ONO KAZUYA (JP)
MORISHITA DAISUKE (JP)
SATOH YOSHIHIKO (JP)
MIZUTANI AKIO (JP)
Application Number:
PCT/JP2023/003154
Publication Date:
August 10, 2023
Filing Date:
February 01, 2023
Export Citation:
Assignee:
ONO PHARMACEUTICAL CO (JP)
CHORDIA THERAPEUTICS INC (JP)
CHORDIA THERAPEUTICS INC (JP)
International Classes:
A61K31/444; A61K31/5025; A61K45/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
WO2020111087A1 | 2020-06-04 | |||
WO2021000855A1 | 2021-01-07 | |||
WO2021241611A1 | 2021-12-02 |
Other References:
FENG SONG, ZHANG HAISHEN, TANG ZHIYONG, PENG XINGAO, YANG MIN, WEI XUDONG, ZHONG WENGE: "Direct Construction of Chiral Ether via Highly Efficient Heck Reaction and N-Directed Asymmetric Hydrogenation for Large-Scale Synthesis of MALT1 Inhibitor RGT-068A", ORGANIC PROCESS RESEARCH & DEVELOPMENT, AMERICAN CHEMICAL SOCIETY, US, vol. 26, no. 11, 18 November 2022 (2022-11-18), US , pages 3089 - 3095, XP093083206, ISSN: 1083-6160, DOI: 10.1021/acs.oprd.2c00229
Attorney, Agent or Firm:
KAMADA, Mitsunori et al. (JP)
Download PDF: